ProMIS Neurosciences Inc PMN

Brings back memories

[retiredcop]

FDA gives fast track approval for Biogen's ALS treatment.  Not sure if anyone's remember but around 2008-2009 Biogen gave AMF A few million to licence out our sod1 science for ALS. Biogen didn't do anything with the science and eventually AMF just did not renew the licencing agreement .  Again PMN will benefit from this FDA approval... one of our ALS treatment being developed is also based on sod1 so we now have something to compare with...win win situation

[retiredcop]

Dr Cashman presented on ALS with reference to Sod1. The presentation maybe on the PMN website now. Title: RACK1 Knockdown Is a Potential Therapeutic Target in ALS and FTLD-TDP Session: P1: Aging and Dementia: Basic Science (abstract #3494) Presenter: Neil Cashman, M.D. Date & Time: April 23, 2023 from 8:00 – 9:00 a.m. ET ProMIS has evaluated RACK1 as a

[retiredcop]

Summary from dr. Cashman preaentation Summary • ProMIS monoclonal antibodies selective for misfolded RACK1 (RACK1mis mAb) showed coaggregation of RACK1 and TDP-43 in ALS and FTLD-TDP, and in cell culture; • RACK1 knockdown alleviated TDP-43 aggregation as well as associated global translational suppression in cultured cells; • RACK1 knockdown was well-tolerated in cultured cells in vitro

[M101]

That could be part of the reason for today's decent volume after the little reversal yesterday, maybe investors are starting to think about the platform.  It's probably nothing, but maybe it's going to rhyme with last July's trading pattern and lead into a long term higher floor.